EBS News and Press, Emergent Biosolutions Inc. From 04/23/20

Johnson & Johnson (NYSE: JNJ ) says it will work with Emergent BioSolutions (NYSE: EBS ) to produce more than a billion doses of a COVID-19 vaccine candidate, as it seeks to scale up global manufacturing of its potential treatment. More news on: Johnson & Johnson, Emergent BioSol...

Johnson & Johnson (NYSE: JNJ) signed a contract to pay Emergent BioSolutions (NYSE: EBS) $135 million to help manufacture its vaccine to treat COVID-19 , the disease caused by the novel coronavirus. In addition to developing its own drugs aimed at combating bioterrorism and emergin...

Emergent will provide contract development and manufacturing services to support Johnson & Johnson’s commitment of one billion doses of vaccine for worldwide emergency pandemic use Agreement valued at approximately $135 million GAITHERSBURG, Md., April 23, 2020 (GLOBE NEWSWI...

Market Pulse The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around...

One of our long-standing recommendations, Emergent BioSolutions ( EBS ) is in the thick of the effort to help in the fight against Covid-19, notes Tom Bishop , editor of BI Research . There are many companies currently working on vaccines for COVID-19. If they are succes...

GAITHERSBURG, Md., April 16, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 30, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2020, recent business developments, revenue guidance for t...

CSL Behring (OTC: CSLLY) and Takeda Pharmaceutical (NYSE: TAK) are joining forces with four other companies -- Biotest, Bio Products Laboratory, LFB, and Octapharma -- to develop a plasma-derived antibody treatment they hope will prove effective against COVID-19, the disease caused ...

To be sure, no drug has yet been proven to be effective in treating novel coronavirus disease COVID-19. Any claims that you might read online about one drug or another being a silver bullet for the disease are premature at best. However, what is true right now is that several companies are dev...

GAITHERSBURG, Md., April 06, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Nina DeLorenzo to the position of senior vice president for global public affairs. DeLorenzo will oversee external relations, corporate communications, advocacy,...

The Food and Drug Administration is encouraging people who have recovered from COVID-19 , the disease caused by the novel coronavirus, to donate their blood plasma, which can be processed into an antibody product that can treat current patients. Based on the medical community's experience with...